Patrick J. Hayden on Muck Rack

Patrick J. Hayden

  • Commercial Finance Analyst, William Grant & Sons
London, United Kingdom
As seen in: Color Research & Application, Nature, Wiley Online Library, Bandcamp Daily, Educational Studies, Expert Review of Anticancer Therapy, Gulf News, Royal Society of Chemistry, The Lancet, Physical Review B and
Reggae Artist. Her's my BiO: hypeddit.com/phayden
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Patrick J.

Contact Patrick J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

|
By Isabel Sánchez-Ortega, Patrick J. Hayden, Laurent Garderet, Anna Sureda, Fabio Ciceri, Donal McLornan, Krzysztof Kałwak, Antonio M. Risitano, Francesco Onida, Ibrahim Yakoub-Agha, Ali Bazarbachi, Annalisa Ruggeri, Alessandro Criscimanna, Jacques-Emanuel Galimard
| Nature Verified
Abstract The therapeutic landscape of hematological malignancies has been transformed by targeted therapies, immunotherapy, and cellular therapies, leading to more complex and prolonged clinical courses. Currently, there is substantial variability in how “lines of therapy” (LoT) are defined and recorded, which hinders research and data harmonization.
Open in Who Shared Issue with article?

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

|
By Nico Gagelmann, Maximilian Merz, Laurien Baaij, Linda Koster, Joanna Drozd-Sokolowska, Kavita Raj, Jürgen Kuball, Patrick J. Hayden, Florent Malard, Laurent Garderet, Annalisa Ruggeri, Donal McLornan, Jorinde D. Hoogenboom
| Nature Verified
To the Editor: Consequently, most candidates for anti-BCMA CAR-T receive “bridging therapy” to control disease and maintain performance status while awaiting infusion [1]. However, practices remain highly individualized, with choices driven by disease tempo, prior therapies, comorbidities, and center experience [2]. Furthermore, pivotal trials allowed only limited regimens, leaving a gap between trial constraints and the breadth of strategies used in practice [3,4,5].
Open in Who Shared Issue with article?

Dissemination of One’s Own Misstatements Does Not Create Scheme Liability, Says New York Court | JD Supra

|
By Luke Cadigan, Patrick J. Hayden, Samantha Kirby
| JD Supra
On July 16, 2025, the US District Court for the Eastern District of New York dismissed a scheme liability claim in an enforcement action brought by the US Securities and Exchange Commission (SEC) against a company’s former chief financial officer (CFO). The SEC alleged that the CFO engaged in “deceptive conduct” by disseminating his own alleged misstatements to investors as part of a scheme to fundraise for the company.
Open in Who Shared Issue with article?
See all 256 licensed articles (258 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified